HER2-positive Breast Cancer Registry

Recruiting

• Conditions: HER2 + Breast Cancer

• Registration Number: NCT06603597
• Lead Sponsor: Priyanka Sharma

Brief Summary

The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-09
• Study First Submitted: 2024-09-16
• Study First Submitted QC: 2024-09-16
• Study First Posted: 2024-09-19
• Study Start: 2024-09-27
• Last Update Submitted: 2024-09-30
• Last Update Posted: 2024-10-03
• Primary Completion: 2044-10
• Study Completion: 2044-10

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Stage I-IV HER2-positive breast cancer

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival rate	From diagnosis to 5 years after diagnosis	For patients with stage I-III HER2-positive breast cancer, percentage of patients who are alive at 5 years after diagnosis.

Secondary Outcome Measures

Name	Time	Method
Pathologic complete response rate	From start of neoadjuvant systemic treatment until approximately 8 months after start of neoadjuvant systemic treatment	Percentage of patients with stage I-III HER2-positive breast cancer who received neoadjuvant systemic therapy and experienced pathologic complete response.

Trial Locations

Locations (5)

KUCC - Indian Creek; 🇺🇸 Overland Park, Kansas, United States

KCCC Overland Park; 🇺🇸 Overland Park, Kansas, United States

KUCC - North; 🇺🇸 Kansas City, Missouri, United States

KUCC - Lee's Summit; 🇺🇸 Lee's Summit, Missouri, United States

The University of Kansas Cancer Center; 🇺🇸 Westwood, Kansas, United States